Despite significant advances in the systemic treatment of metastatic renal cell carcinoma, long-term survival remains low.
A potential way to improve outcomes in selected cases is the use of metastasectomy, which is part of the multimodal treatment of this disease. Although the evidence supporting this approach is limited, we believe it is a reasonable option for certain patients. This review summarizes the evidence supporting this approach.
Written by:
Josephides E, Rodriguez-Vida A, Galazi M, Chowdhury S, Suder A. Are you the author?
Department of Medical Oncology, Guy's Hospital, London, SE1 9RT, UK.
Reference: Expert Rev Anticancer Ther. 2013 Dec;13(12):1363-71.
doi: 10.1586/14737140.2013.856762
PubMed Abstract
PMID: 24236818
UroToday.com Renal Cancer Section
